Press Release Details

Cerus Corporation Announces Second Quarter Results

August, 02 2005

CONCORD, Calif. -- Cerus Corporation (Nasdaq:CERS) today announced results for the second quarter ended June 30, 2005. Revenues for the second quarter were $5.5 million, up from $3.8 million for the second quarter of 2004, primarily due to amounts recognized in the current period from past up-front payments from BioOne Corporation and MedImmune, Inc., for which revenue recognition was deferred. Total operating expenses for the second quarter of 2005 were $8.5 million, down from $14.1 million for the same period in 2004, due primarily to the effects of the strategic realignment implemented June 2004.

Net loss for the second quarter of 2005 was $2.8 million, or $0.12 per share, compared to a net loss of $11.5 million, or $0.52 per share, for the second quarter of 2004. The net loss in the current period reflects both increased funding for research and development programs and reduced operating expenses, as well as a significant reduction in interest expense as a result of the February 2005 settlement of the loan dispute with Baxter Capital. "The results from the second quarter reflect both a broadening of funding sources and success in managing expenses," said Claes Glassell, president and CEO of Cerus Corporation. "We remain comfortable with guidance of approximately $45 million of cash and marketable securities at year end."

For the six months ended June 30, 2005, total revenues were $11.9 million, compared to $7.4 million for the same period in 2004. Net income was $18.6 million, or $0.80 per diluted share for the six months ended June 30, 2005, compared to a net loss of $20.7 million or $0.94 per share for that same period in 2004. Net income for the six-month period in 2005 includes a one-time gain of $22.1 million recognized in February 2005 as a result of the loan settlement. At June 30, 2005, the company had cash, cash equivalents and short-term investments of $52.2 million.


The company has scheduled its quarterly conference call for 4:30 p.m. Eastern time today. Interested parties can access a live Internet broadcast at For those unable to listen to the live broadcast, the call will be temporarily archived.


Cerus Corporation is developing novel products for cancer, infectious disease and blood safety based on multiple, innovative technology platforms. The company is building a pipeline of next generation cancer immunotherapies by combining its proprietary attenuated Listeria vector platform with promising disease antigens. These products are designed to stimulate innate and T cell immune pathways, generating highly potent anti-tumor responses. Cerus is applying its Helinx technology to develop the INTERCEPT Blood System, which is designed to enhance the safety of blood components through pathogen inactivation. The company's strategy is to leverage the broad potential of its technologies and products through alliances. Cerus' partners to date include MedImmune and Johns Hopkins University for cancer immunotherapy, and Baxter International and BioOne for the INTERCEPT Blood System.

Helinx is a trademark of Cerus Corporation.

Baxter and INTERCEPT are trademarks of Baxter International Inc.

Statements in this news release regarding our outlook and expected financial performance, the availability of cash resources to fund operating expenses and capital needs and our relationship with partners are forward-looking statements that involve risks and uncertainties. Actual results could differ materially from the above forward-looking statements as a result of certain factors, including the risks and uncertainties inherent in developing biotechnology products based on new technologies, the timing and results of our clinical trials and development activities related to our vaccine programs, market acceptance of our products, actions by domestic and foreign regulatory authorities at any stage of the development process, the availability of governmental or third party reimbursement for the use of our products, the size of the markets for our products, our reliance on our relationship with Baxter, manufacturing capabilities, our reliance on our relationship with BioOne, our ability to complete our clinical trials, our successful completion of our product components' commercial design, our ability to demonstrate a sufficient shelf-life of our product components, development and testing of additional configurations of our products, product liability, our limited operating history, additional financing activities, protection of our intellectual property rights, our use of hazardous materials in the development of our products, volatility in our stock price, legal proceedings, on-going compliance with the requirements of the Sarbanes-Oxley Act of 2002 and other factors discussed in the company's Form 10-K/A for fiscal 2004, as well as in other reports subsequently filed from time to time with the Securities and Exchange Commission. The Company assumes no obligation to update any forward-looking statements.


Condensed Statements of Operations
(in thousands, except per share
 information)                    Three Months Ended  Six Months Ended
                                       June 30,           June 30,
                                   2005      2004     2005      2004
                                 --------  -------- -------- ---------
Revenue                          $ 5,480  $  3,766  $11,881  $  7,413

Operating expenses:
     Research and development      5,881     8,720   10,930    17,388
     General and administrative    2,616     2,919    5,037     5,962
     Restructuring                     -     2,465        -     2,465
                                 -------- --------- -------- ---------
       Total operating expenses    8,497    14,104   15,967    25,815
                                 -------- --------- -------- ---------
         Loss from operations     (3,017)  (10,338)  (4,086)  (18,402)
Gain on loan settlement                -         -   22,089         -
Interest income (expense), net       256    (1,209)     621    (2,339)
                                 -------- --------- -------- ---------
         Net income (loss)        (2,761)  (11,547)  18,624   (20,741)
                                 ======== ========= ======== =========

Net income (loss) per share -
 basic                            ($0.12)   ($0.52) $  0.84    ($0.94)
                                 ======== ========= ======== =========
Net income (loss) per share -
 diluted                          ($0.12)   ($0.52) $  0.80    ($0.94)
                                 ======== ========= ======== =========
Shares used in computing
 Net income (loss) per share -
  basic                           22,321    22,113   22,289    22,099
                                 ======== ========= ======== =========

Shares used in computing net
 income (loss) per share -
 diluted                          22,321    22,113   23,343    22,099
                                 ======== ========= ======== =========

Condensed Balance Sheets                        June 30,  December 31,
(in thousands)                                    2005        2004
                                               ---------  ------------

Cash, cash equivalents and short-term
 investments                                   $ 52,175     $  95,334
Accounts receivable from a related party            290             4
Accounts receivable and other current assets      4,170         4,533
Furniture and equipment, net                        890           947
Other assets                                      1,260         1,260
                                               ---------    ----------

  Total assets                                 $ 58,785     $ 102,078
                                               =========    ==========

Accounts payable and other current liabilities $  5,256     $   6,087
Accounts payable to a related party                   -           196
Current payable to a related party                    -        34,500
Deferred gain on loan settlement                      -        22,089
Deferred revenue                                  8,549        13,217
Long-term debt and accrued interest,
 payable to a related party                       4,646         4,500
Stockholders' equity                             40,334        21,489
                                               ---------    ----------

  Total liabilities and stockholders' equity   $ 58,785     $ 102,078
                                               =========    ==========

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600